2Yrd. Doç. Dr., İstanbul Medipol Üniversitesi Göz, İstanbul, Türkiye
3Prof. Dr., İstanbul Medipol Üniversitesi Göz, İstanbul, Türkiye
4Uz. Dr., Özel İnci Göz Hastanesi, Göz, Sakarya, Türkiye
5Yrd. Doç. Dr., Sağlık Bilimleri Üniversitesi, Göz, İstanbul, Türkiye Purpose: To compare the efficacy of intravitreal injection of ranibizumab and afl ibercept on the treatment of macular edema due to branch retinal vein occlusion (BRVO).
Materials and Methods: In this retrospective study; eyes with macular edema secondary to BRVO which treated with intravitreal ranibizumab (IVR) or afl ibercept( IVA) and followed at least 12 months between September 2012 and March 2016 were reviewed. Mean number of injections and changes in two groups? best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by optical coherence tomography at month 1, 3, 6 and 12 were reviewed and compared.
Results: Mean BCVA improved significantly in IVR group (p=0.03, 0.04, 0.02 and 0.03 respectively) and IVA group (p=0.02, 0.04, 0.03 and 0.03 respectively ; and CMT decreased signifi cantly in IVR group (p=0.02, 0.02, 0.02 and 0.03 respectively) and IVA group (p=0.001, 0.03, 0.01 and 0.02 respectively) at 1, 3, 6 and 12th months. Mean number of injections per eye within twelve months were 3.4±1.2 in ranibizumab group, and 2.2±1.1 in afl ibercept group (p=0.03). There were no significant differences between two groups at month 12, including final BCVA, changes in BCVA, final CMT, and changes in CMT (p> 0.05)
Conclusion: Aflibercept presented similar decrease in CMT and improvement in BCVA with lesser number of injections for macular edema due to BRVO.
Keywords : Branch retinal vein occlusion, macular edema, ranibizumab, aflibercept